(via NewsDirect)

Avecho Biotechnology Limited (ASX:AVE) CEO Dr Paul Gavin speaks with Proactive after announcing that the company is looking to raise approximately $11 million. Proceeds from the raise will be used to fund a pivotal Phase 3 clinical trial designed to test the company’s proprietary CBD soft-gel capsule for the treatment of insomnia.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases